142 related articles for article (PubMed ID: 10410196)
1. Comment: cidofovir in the treatment of cytomegaloviral disease.
Buchanan J; Davis LJ
Ann Pharmacother; 1999 Jun; 33(6):752-3. PubMed ID: 10410196
[No Abstract] [Full Text] [Related]
2. Cidofovir.
Jabs DA
Arch Ophthalmol; 1997 Jun; 115(6):785-6. PubMed ID: 9194731
[No Abstract] [Full Text] [Related]
3. A preclinical and clinical overview of the nucleotide-based antiviral agent cidofovir (HPMPC).
Lalezari JP; Stagg RJ; Jaffe HS; Hitchcock MJ; Drew WL
Adv Exp Med Biol; 1996; 394():105-15. PubMed ID: 8815677
[No Abstract] [Full Text] [Related]
4. Cidofovir. Review of current and potential clinical uses.
Safrin S; Cherrington J; Jaffe HS
Adv Exp Med Biol; 1999; 458():111-20. PubMed ID: 10549383
[No Abstract] [Full Text] [Related]
5. Successful use of cidofovir in treating AIDS-related cytomegalovirus retinitis, encephalitis, and esophagitis.
Blick G; Garton T; Hopkins U; LaGravinese L
J Acquir Immune Defic Syndr Hum Retrovirol; 1997 May; 15(1):84-5. PubMed ID: 9215660
[No Abstract] [Full Text] [Related]
6. Current and experimental therapeutic options for cytomegalovirus disease.
Flaherty JF
Am J Health Syst Pharm; 1996 Apr; 53(8 Suppl 2):S4-11. PubMed ID: 8728375
[No Abstract] [Full Text] [Related]
7. Successful treatment of cytomegalovirus encephalitis in an AIDS patient using cidofovir.
Sadler M; Morris-Jones S; Nelson M; Gazzard BG
AIDS; 1997 Aug; 11(10):1293-4. PubMed ID: 9256949
[No Abstract] [Full Text] [Related]
8. (S)-1-(3-hydroxy-2-(phosphonylmethoxy)propyl)cytosine (HPMPC): a potent antiherpesvirus agent.
Bronson JJ; Ferrara LM; Hitchcock MJ; Ho HT; Woods KL; Ghazzouli I; Kern ER; Soike KF; Martin JC
Adv Exp Med Biol; 1990; 278():277-83. PubMed ID: 1963042
[No Abstract] [Full Text] [Related]
9. Treatment of cytomegalovirus retinitis in patients with AIDS.
Jabs DA
Ann Intern Med; 1996 Jul; 125(2):144-5. PubMed ID: 8678370
[No Abstract] [Full Text] [Related]
10. Hypotony and visual loss with intravenous cidofovir treatment of cytomegalovirus retinitis.
Friedberg DN
Arch Ophthalmol; 1997 Jun; 115(6):801-2. PubMed ID: 9194736
[No Abstract] [Full Text] [Related]
11. Cidofovir for cytomegalovirus-preemptive therapy in stem cell transplant recipients.
Kiehl MG; Basara N
Blood; 2001 Sep; 98(5):1626; author reply 1628. PubMed ID: 11547768
[No Abstract] [Full Text] [Related]
12. Failure of cidofovir to reduce CMV-antigenemia in a child transplanted from a matched unrelated donor.
Castagnola E; Cristina E; Dallorso S; Lanino E; Giacchino R
J Chemother; 2001 Feb; 13(1):100-1. PubMed ID: 11233794
[No Abstract] [Full Text] [Related]
13. Treatment of BK virus-associated hemorrhagic cystitis and simultaneous CMV reactivation with cidofovir.
Held TK; Biel SS; Nitsche A; Kurth A; Chen S; Gelderblom HR; Siegert W
Bone Marrow Transplant; 2000 Aug; 26(3):347-50. PubMed ID: 10967578
[TBL] [Abstract][Full Text] [Related]
14. Cidofovir for cytomegalovirus retinitis.
Kravcik S
Ann Intern Med; 1997 Sep; 127(6):490-1. PubMed ID: 9313009
[No Abstract] [Full Text] [Related]
15. Cidofovir in the treatment of cytomegaloviral disease.
Kendle JB; Fan-Havard P
Ann Pharmacother; 1998 Nov; 32(11):1181-92. PubMed ID: 9825085
[TBL] [Abstract][Full Text] [Related]
16. Susceptibility of human cytomegalovirus to cidofovir is unchanged after limited in vivo exposure to various regimens of drug.
Cherrington JM; Miner R; Hitchcock MJ; Lalezari JP; Drew WL
J Infect Dis; 1996 Apr; 173(4):987-92. PubMed ID: 8603981
[TBL] [Abstract][Full Text] [Related]
17. Cytomegalovirus drug resistance.
Emery VC
Antivir Ther; 1998; 3(4):239-42. PubMed ID: 10682146
[TBL] [Abstract][Full Text] [Related]
18. Cytomegalovirus: disease syndromes and treatment.
Drew WL; Lalezari JP
Curr Clin Top Infect Dis; 1999; 19():16-29. PubMed ID: 10472478
[No Abstract] [Full Text] [Related]
19. Value of animal models to evaluate agents with potential activity against human cytomegalovirus.
Kern ER
Transplant Proc; 1991 Jun; 23(3 Suppl 3):152-5, discussion 155. PubMed ID: 1648821
[No Abstract] [Full Text] [Related]
20. Comparative effect of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine treatment on cytomegalovirus-induced interstitial pneumonitis in allogeneic bone marrow transplant recipient rats.
Stals FS; Zeytinoglu A; Havennith M; de Clercq E; Bruggeman CA
Transplant Proc; 1993 Feb; 25(1 Pt 2):1248-9. PubMed ID: 8382855
[No Abstract] [Full Text] [Related]
[Next] [New Search]
